CDMO

Samsung Biologics Q1 2026 Results were officially released today, marking a significant milestone for the Incheon-based contract development and manufacturing organization (CDMO). The company reported a consolidated revenue of KRW 1,257.1 billion, representing a robust 25.8% increase year-over-year. With full operations in plants at our Bio Campus I and Plant 5 ramp-up underway, we are further strengthening manufacturing readiness. John Rim, President and CEO Detailed Financial Performance: Samsung Biologics Q1 2026 Results The financial data for the first quarter reflects the company's ability to maintain high utilization rates across its massive capacity. Operating profit saw a substantial jump, reaching KRW 580.8 billion. MetricQ1'26 (KRW Billion)Q1'25 (KRW Billion)YoY ChangeTotal Revenue1,257.1999.5+25.8%Operating Profit580.8430.2+35.0%EBITDA675.3514.6+31.2%Net Profit452.4*360.1*+25.6% Learn More: Samsung Biologics Reports Q4 Results, Achieves Record KRW 4.5 Trillion Revenue in 2025, Sets Sights on U.S. Expansion Operational Milestones and U.S. Market Entry A core driver behind the Samsung Biologics Q1 2026 Results was the strategic acquisition of the Rockville manufacturing facility in Maryland, U.S., for USD 353 million. This move establishes the company’s first physical manufacturing footprint in the United States, bringing them closer to a major cluster of biopharmaceutical clients. Key operational highlights include: Full Utilization: Plants 1 through 4 are operating at maximum capacity. ADC Facility Success: Completion of the first commercial-scale engineering run for Antibody-Drug Conjugates (ADCs). Plant 5 Progress: Construction and ramp-up remain on track to meet future demand. Strategic Partnerships and Regulatory Excellence Beyond the financials, the Samsung Biologics Q1 2026 Results highlight the company’s role in global health. A new partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) focuses on rapid response manufacturing, while a collaboration with Eli Lilly and Company aims to bolster the biotechnology ecosystem. Regulatory and Service Capacity Data The following table outlines the company's growing clinical and regulatory footprint as of the end of Q1 2026. CategoryQ1 2026 StatusSignificanceCumulative Regulatory Approvals440+Demonstrates global quality complianceCumulative Contract ValueUSD 21.4 BillionLong-term revenue visibilityADC Modality ReadinessCommercial ScaleExpansion into high-growth drug classesEcoVadis Sustainability RatingPlatinumTop 1% of companies globally Future Outlook: Sustaining Momentum Looking ahead, the company is maintaining its 2026 guidance. The integration of CDO services (Internal Link), such as master cell bank production and vector construction, is expected to provide a "one-stop" solution for emerging biotech firms. With the Samsung Biologics Q1 2026 Results setting a high bar, the focus for the remainder of the year will be on the "Bio Campus II" development and further diversifying the manufacturing network to meet regional supply needs. By combining operational consistency with aggressive global expansion, Samsung Biologics continues to cement its position as the world's leading CDMO. Company: Samsung Biologics

Category: CDMO

Samsung Biologics Q1 2026 Results: Record Growth and Strategic U.S. Expansion

Areas Covered

Discover More

GSK and Spero Therapeutics Secure Historic Utebzi FDA Approval for Adults with Complicated Urinary Tract Infections

Novo Nordisk Cyber Attack: Threat Group Demands $25 Million Ransom Following Massive Data Breach

Eli Lilly Announces Landmark Phase 3 Trial Results for Lilly Jaypirca CLL Treatment

FDA Announces AstraZeneca Truqap Prostate Cancer Approval for PTEN-Deficient Patients

Johnson & Johnson TALVEY Multiple Myeloma Treatment Shows Unprecedented Phase 3 MonumenTAL-3 Efficacy

Novo Nordisk IT Security Incident: Unauthorized System Access Detected in Denmark